Golden
Stemline Therapeutics

Stemline Therapeutics

A biopharmaceutical company developing therapeutics to attack cancer stem cells.

Stemline Therapeutics is a publicly traded, New York City based clinical stage biopharmaceutical company which develops novel oncology therapeutics that was founded in 2003 by Eric Rowinsky and Ivan Bergstein. As of December 2018, the company is developing three clinical stage products candidates, SL-401, SL-801, and SL-701.

Products

SL-401

SL-401, also known as ELZONRIS, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a wide range of malignancies. A Phase 2 Trial with SL-401 is enrolling patients with BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm).

ELZONRIS

Stemline has submitted a rolling Biologics License Application (BLA) to the FDA for ELZONRIS, which has been granted breakthrough therapy designation (BTD) for the treatment of BPDCN. If successful, the company anticipates the acceptance of the BLA within 60 days of submission and potential U.S. marketing approval by the first quarter of 2019.

SL-801

SL-801 is a novel oral small molecule reversible inhibitor of nuclear transport protein. It is in Phase 1 clinical trial for the treatment of solid and hematological cancers.

SL-801

SL-701 is an immunotherapy designed to activate the immune system to attack tumors. Phase 2 trials in adult patients with second-line glioblastoma mutiforme (GBM) has been completed. The data and next steps for the program are being evaluated.

IL-3R-targeted compounds

Two other product candidates are also in Stemline's pipeline, SL-501 and SL-101, two next generation IL-3R-targeted compounds. The company has also constructed an innovative drug discovery platform (StemScreen).

Funding

Series A

On April 9, 2008 Stemline Therapeutics completed their series A funding round with $12.5 million in funding from Prequot Capital. 

Venture

On March 29, 2010 Stemline Therapeutics completed a venture capital funding round with $1.3 million in funding from undisclosed investors. 

Timeline

March 29, 2010

Venture funding round

On March 29, 2010 Stemline Therapeutics completed a venture capital funding round with $1.3 million in funding from undisclosed investors. 

April 9, 2008

Series A funding round

On April 9, 2008 Stemline Therapeutics completed their series A funding round with $12.5 million in funding from Prequot Capital. 

Funding rounds

2 Results
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

David Gionco

VP of Finance and Chief Accounting Officer



Ivan Bergstein, M.D.

CEO



Kenneth Hoberman

COO



Further reading

Title
Author
Link
Type
Date

Austin's Mirna Therapeutics raises $41 million

Lori Hawkins

Web



Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock

Stemline Therapeutics, Inc.

Web



The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%

Sean Williams

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References